drugset / Trial / NCT05852769

A Study to Evaluate the Drug-drug Interaction Potential of BMS-986196 in Healthy Participants

NCT05852769 ↗

Phase 1 Completed 18 enrolled Bristol-Myers Squibb
NaSequentialOpen-labelTreatment

Summary

This study is designed to assess the effect of BMS-986196 on the drug levels of caffeine, montelukast, flurbiprofen, omeprazole, midazolam, digoxin, and pravastatin in healthy participants.

Timeline

Start
2023-05-31
Primary completion
2023-08-24
Completion
2023-08-24

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986196 Unknown — —
Subject Caffeine Small molecule — —
Subject Digoxin Other / unclassified — —
Subject Flurbiprofen Small molecule — —
Subject Midazolam Small molecule — —
Subject Montelukast Other / unclassified — —
Subject Omeprazole Other / unclassified — —
Subject Pravastatin Small molecule — —

Indications

No indication recorded.